Table: q1_q4_2020_prescription_drugs_wac_increases , manufacturer_name like N*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000106 Neos Therapeutics, Inc. 09/30/2020 70165002030 Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 12.5 MG 07/06/2020 36.00 396.00 06/28/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved. All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer.
Rx0000106 Neos Therapeutics, Inc. 09/30/2020 70165002530 Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 15.7 MG 07/06/2020 36.00 396.00 06/28/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved. All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer.
Rx0000106 Neos Therapeutics, Inc. 09/30/2020 70165003030 Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 18.8 MG 07/06/2020 36.00 396.00 06/28/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved. All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer.
Rx0000106 Neos Therapeutics, Inc. 09/30/2020 70165000530 Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 3.1 MG 07/06/2020 36.00 396.00 06/28/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved. All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer.
Rx0000106 Neos Therapeutics, Inc. 09/30/2020 70165001030 Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 6.3 MG 07/06/2020 36.00 396.00 06/28/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved. All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer.
Rx0000106 Neos Therapeutics, Inc. 09/30/2020 70165001530 Adzenys XR-ODT Oral Tablet Extended Release Disintegrating 9.4 MG 07/06/2020 36.00 396.00 06/28/2032 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Please note that California has stated that in their review of the WAC that an increase took place on December 31, 2018 vs. January 1, 2019, as indicated by Neos Therapeutics. Please note that the increase actually took place on 1/1/2019, however there was an issue with one of the databanks loading it early. This is an issue with the databank and Neos has been working with the Databank in attempt to get the issue resolved. All of the acquisition related fields were left blank as Neos is the “original” marketer of this product and it was not acquired from another manufacturer.
Rx0000106 Neos Therapeutics, Inc. 03/31/2020 70165020030 COTEMPLA XR-ODT 17.3MG 30 Tabs/Bottle 01/01/2020 49.11 420.00 06/28/2032 Single Source Drug None 1 The price increase on Cotempla XR was taken to support factors impacting the business including increased manufacturing costs, increased cost from operations and increased distribution costs. None No Significant Change/Improvement to Drug None None None None None None None None None None None This drug has not been acquired.
Rx0000106 Neos Therapeutics, Inc. 03/31/2020 70165030030 COTEMPLA XR-ODT 25.9MG 30 Tabs/Bottle 01/01/2020 49.11 420.00 06/28/2032 Single Source Drug None 1 The price increase on Cotempla XR was taken to support factors impacting the business including increased manufacturing costs, increased cost from operations and increased distribution costs. None No Significant Change/Improvement to Drug None None None None None None None None None None None This drug has not been acquired.
Rx0000106 Neos Therapeutics, Inc. 03/31/2020 70165010030 COTEMPLA XR-ODT 8.6MG, 30 Tabs/Bottle 01/01/2020 49.11 420.00 06/28/2032 Single Source Drug None 1 The price increase on Cotempla XR was taken to support factors impacting the business including increased manufacturing costs, increased cost from operations and increased distribution costs. None No Significant Change/Improvement to Drug None None None None None None None None None None None This drug has not been acquired.
Rx0000204 Noden Pharma USA, Inc. 06/30/2020 70839015030 Tekturna 150mg aliskirin tablets 30 tablet bottle 04/20/2020 16.62 224.42 02/19/2026 Innovator Multiple Source Drug None 1 None 1 None 1 07/01/2016 Novartis AG 199000000 None includes milestones, other non-included milestone payments. Acquired the worldwide rights to tekturna/rasilez. 150.19 133.66 2007 58.50 None None
Rx0000204 Noden Pharma USA, Inc. 06/30/2020 70839030030 Tekturna 300mg aliskirin tablets 30 tablet bottle 04/20/2020 20.97 283.13 02/19/2026 Innovator Multiple Source Drug None 1 None 1 None 1 07/01/2016 Novartis AG 199000000 None includes milestones, other milestones not included. Acquired the worldwide rights to tekturna/rasilez. 189.48 172.41 2007 73.80 None None
Rx0000204 Noden Pharma USA, Inc. 06/30/2020 70839011230 Tekturna HCT oral tablet 150mg aliskirin/12.5mg hydrochlorthiazide 30 tablet bottle 04/20/2020 16.62 224.42 07/13/2028 Single Source Drug None 1 None 1 None 1 07/01/2016 Novartis AG 199000000 None includes milestones, other milestones not included. Acquisition of worldwide rights to tekturna/rasilez. 150.19 136.66 2008 62.01 None None
Rx0000204 Noden Pharma USA, Inc. 06/30/2020 70839012530 Tekturna HCT oral tablet 150mg aliskirin/25mg hydrochlorothiazide 30 tablet bottle 04/20/2020 16.62 224.42 07/13/2028 Single Source Drug None 1 None 1 None 1 07/01/2016 Novartis AG 199000000 None includes milestones, other milestones not included. Acquisition of entire worldwide rights to tekturna/rasilez. 150.19 136.66 2008 62.01 None None
Rx0000204 Noden Pharma USA, Inc. 06/30/2020 70839031230 Tekturna HCT oral tablet 300mg aliskirin/12.5mg hydrochlorothiazide 30 tablet bottle 04/20/2020 20.97 283.13 07/13/2028 Single Source Drug None 1 None 1 None 1 07/01/2016 Novartis AG 199000000 None includes milestones, other milestones not included. acquisition of entire worldwide rights to tekturna/rasilez 189.48 172.41 2008 78.23 None None
Rx0000204 Noden Pharma USA, Inc. 06/30/2020 70839032530 Tekturna HCT oral tablet 300mg aliskirin/25mg hydrochlorothiazide 30 tablet bottle 04/20/2020 20.97 283.13 07/13/2028 Single Source Drug None 1 None 1 None 1 07/01/2016 Novartis AG 199000000 None includes milestones, other milestones not included. Acquisition of entire worldwide rights to tekturna/rasilez 189.48 172.41 2008 78.23 None None
Rx0000226 Nostrum Laboratories, Inc. 06/30/2020 29033002602 Calcium Acetate Oral Capsule 667mg 200count 06/25/2020 90.36 140.36 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None The Product was not acquired.
Rx0000226 Nostrum Laboratories, Inc. 03/31/2020 29033002901 Pindolol Oral Tablets, 10mg - 100ct 01/06/2020 287.95 431.81 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None We did not acquire this item. We developed it at Nostrum
Rx0000226 Nostrum Laboratories, Inc. 03/31/2020 29033002801 Pindolol Oral Tablets, 5mg - 100ct 01/06/2020 263.48 369.06 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None We did not acquire this item. We developed it at Nostrum.
Rx0000226 Nostrum Laboratories, Inc. 03/31/2020 70408014634 Promethazine HCL Oral Solution, 6.25mg/5mL - 473mL 01/13/2020 159.56 170.55 None Non-innovator Multiple Source Drug None 1 None 1 None 1 12/11/2015 Sun Pharmaceuticals None 1 None 10.99 10.99 2009 10.99 None None
Rx0000073 Novartis 03/31/2020 00065027510 Azopt 1% Drops 10mL, 10pk 01/03/2020 16.96 325.34 None Single Source Drug 95822 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00065027515 Azopt 1% Drops 15mL, 15pk 01/03/2020 25.44 487.96 None Single Source Drug 95822 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00065853302 CIPRODEX 0.3% / 0.1%, Drops, 7.5pk 01/03/2020 12.99 249.09 06/04/2025 Single Source Drug 2459065 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078063968 Cosentyx 150mg/ml (Sensoready Pen x1) 01/03/2020 362.52 5541.43 05/05/2033 Single Source Drug 123823 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078063941 Cosentyx 150mg/ml (Sensoready Pen x2) 01/03/2020 362.52 5541.43 05/05/2033 Single Source Drug 615929 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078063997 Cosentyx 150mg/ml (Syringe x1) 01/03/2020 362.52 5541.43 05/05/2033 Single Source Drug 25407 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078063998 Cosentyx 150mg/ml (Syringe x2) 01/03/2020 362.52 5541.43 05/05/2033 Single Source Drug 74145 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00065924007 DUREZOL 0.05% 5mL, Drops, 5pk 01/03/2020 10.26 196.80 None Single Source Drug 1019407 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078065967 Entresto 24/26mg - Tabs, 180 Each Bottle 01/03/2020 106.92 1634.28 11/27/2027 Single Source Drug 35604 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078065920 Entresto 24/26mg - Tabs, 60 Each Bottle 01/03/2020 35.64 544.76 11/27/2027 Single Source Drug 1360497 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078077767 Entresto 49/51mg - Tabs, 180 Each Bottle 01/03/2020 106.92 1634.28 11/27/2027 Single Source Drug 33446 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078077720 Entresto 49/51mg - Tabs, 60 Each Bottle 01/03/2020 35.64 544.76 11/27/2027 Single Source Drug 886774 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078069667 Entresto 97/103mg - Tabs, 180 Each Bottle 01/03/2020 106.92 1634.28 11/27/2027 Single Source Drug 30547 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078069620 Entresto 97/103mg - Tabs, 60 Each Bottle 01/03/2020 35.64 544.76 11/27/2027 Single Source Drug 627167 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078060715 Gilenya, Capsule 0.5mg - 30 each bottle 01/03/2020 451.59 8662.23 09/30/2032 Single Source Drug 318725 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00065175007 Ilevro 0.3%, Drops, 1.7ml per bottle 01/03/2020 15.13 290.21 03/31/2032 Single Source Drug 245494 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00065175014 Ilevro 0.3%, Drops, 3mL per bottle 01/03/2020 15.13 290.21 03/31/2032 Single Source Drug 169319 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078090961 Kisqali + Femara Co-Pack 200 mg, 49 tabs per bottle 01/03/2020 276.16 5297.34 11/09/2031 Single Source Drug 300 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078091661 Kisqali + Femara Co-Pack 400 mg, 70 tabs per bottle 01/03/2020 552.33 10594.71 11/09/2031 Single Source Drug 1176 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078092361 Kisqali + Femara Co-Pack 600 mg, 91 tabs per bottle 01/03/2020 690.41 13243.38 11/09/2031 Single Source Drug 4331 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078086001 Kisqali 200 mg, 21 Tabs per bottle 01/03/2020 276.16 5297.34 11/09/2031 Single Source Drug 4420 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078086742 Kisqali 400 mg, 42 Tabs per bottle 01/03/2020 552.33 10594.71 11/09/2031 Single Source Drug 4568 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078087463 Kisqali 600 mg, 63 Tabs per bottle 01/03/2020 690.41 13243.38 11/09/2031 Single Source Drug 14532 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078066615 Mekinist 0.5 mg 30 tabs per bottle 01/03/2020 182.95 3509.28 01/28/2032 Single Source Drug 20572 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00065427325 PAZEO 0.007 Drops, 2.5mL 01/03/2020 10.71 205.42 05/19/2032 Single Source Drug 1237067 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078068415 Promacta 12.5 mg, 30 tabs per bottle 01/03/2020 344.85 5271.32 02/01/2028 Single Source Drug 8885 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078068515 Promacta 25 mg, 30 tabs per bottle 01/03/2020 344.85 5271.32 02/01/2028 Single Source Drug 35420 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078068615 Promacta 50 mg, 30 tabs per bottle 01/03/2020 624.07 9539.41 02/01/2028 Single Source Drug 46343 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078068715 Promacta 75 mg, 30 tabs per bottle 01/03/2020 936.11 14309.12 02/01/2028 Single Source Drug 23048 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078069899 Rydapt 25 mg - 56 tabs per bottle 01/03/2020 467.55 8968.38 12/02/2030 Single Source Drug 7953 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078069819 Rydapt 25 mg, 112 tabs per bottle 01/03/2020 935.09 17936.75 12/02/2030 Single Source Drug 2769 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00065414727 SIMBRINZA 1% / 0.2%, Drops, 8mL per bottle 01/03/2020 8.95 171.68 10/30/2030 Single Source Drug 872007 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078068266 Tafinlar 50 mg, 120 tabs per bottle 01/03/2020 445.01 8536.05 10/15/2030 Single Source Drug 4352 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078059287 Tasigna 150mg, 28 capsule per bottle, 4 bottles 01/03/2020 962.73 14716.02 10/15/2030 Single Source Drug 21978 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078052687 Tasigna 200mg, 28 capsule per bottle, 4 bottles 01/03/2020 962.73 14716.02 10/15/2030 Single Source Drug 21978 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00065026025 TRAVATAN Z 0.00004, Drops, 2.5mL per bottle 01/03/2020 10.11 193.98 10/13/2029 Innovator Multiple Source Drug 2226281 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00065026005 TRAVATAN Z 0.00004, Drops, 5mL per bottle 01/03/2020 20.22 387.94 10/13/2029 Innovator Multiple Source Drug 456823 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078067119 Tykerb 250 mg, 150 tabs per bottle 01/03/2020 435.48 8353.31 09/18/2029 Single Source Drug 12617 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073 Novartis 03/31/2020 00078067066 Votrient 200 mg 120 tabs per bottle 01/03/2020 719.32 13797.84 10/19/2023 Single Source Drug 33010 None Increases in rate of inflation, continued investment in innovation, post-marketing regulatory commitments, ongoing pharmacovigilance, market conditions and dynamics None Not applicable None None None None None None None None None None None The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis’ related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000017 Noven Therapeutics, LLC 03/31/2020 68968051408 Estradiol & Norethindrone Acetate 0.05-0.14 MG/DAY Patch Twice Weekly 8 EA UU 01/01/2020 15.80 207.41 None Single Source Drug None 1 None 1 None 1 08/13/2014 Novartis None 1 Not a matter of public record 80.50 70.06 1998 23.75 None None
Rx0000017 Noven Therapeutics, LLC 03/31/2020 68968052508 Estradiol & Norethindrone Acetate 0.05-0.25 MG/DAY Patch Twice Weekly 8 EA UU 01/01/2020 15.80 207.41 None Single Source Drug None 1 None 1 None 1 08/13/2014 Novartis None 1 Not a matter of public record. 80.40 69.97 1998 23.75 None None
Rx0000017 Noven Therapeutics, LLC 03/31/2020 68968662508 Estradiol 0.025 MG/24HR Patch Twice Weekly 8 EA UU 01/01/2020 14.96 196.34 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Product was not acquired
Rx0000017 Noven Therapeutics, LLC 03/31/2020 68968663708 Estradiol 0.0375 MG/24HR Patch Twice Weekly 8 EA UU 01/01/2020 14.96 196.34 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Product was not acquired
Rx0000017 Noven Therapeutics, LLC 03/31/2020 68968665008 Estradiol 0.05 MG/24HR Patch Twice Weekly 8 EA UU 01/01/2020 14.96 196.34 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Product was not acquired
Rx0000017 Noven Therapeutics, LLC 03/31/2020 68968667508 Estradiol 0.075 MG/24HR Patch Twice Weekly 8 EA UU 01/01/2020 14.96 196.34 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Product was not acquired
Rx0000017 Noven Therapeutics, LLC 03/31/2020 68968661008 Estradiol 0.1 MG/24HR Patch Twice Weekly 8 EA UU 01/01/2020 14.96 196.34 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Product was not acquired
Rx0000017 Noven Therapeutics, LLC 03/31/2020 68968555203 Methylphenidate 10 MG/9HR Patch 30 EA UU 01/01/2020 30.20 396.32 10/07/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Product was not acquired
Rx0000017 Noven Therapeutics, LLC 03/31/2020 68968555303 Methylphenidate 15 MG/9HR Patch 30 EA UU 01/01/2020 30.20 396.32 10/07/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Product was not acquired
Rx0000017 Noven Therapeutics, LLC 03/31/2020 68968555403 Methylphenidate 20 MG/9HR Patch 30 EA UU 01/01/2020 30.20 396.32 10/07/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Product was not acquired
Rx0000017 Noven Therapeutics, LLC 03/31/2020 68968555503 Methylphenidate 30 MG/9HR Patch 30 EA UU 01/01/2020 30.20 396.32 10/07/2025 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Product was not acquired
Rx0000033 Novo 03/31/2020 00169413212 Ozempic (0.25 or 0.5 MG/DOSE) Subcutaneous Solution Pen-injector 2 MG/1.5ML 01/10/2020 38.62 811.05 06/21/2033 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None NNI holds a number of patents related to Ozempic and has included the expiration date for Patent #10335462 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Ozempic and did not acquire the product from a different company.
Rx0000033 Novo 03/31/2020 00169413602 Ozempic (1 MG/DOSE) Subcutaneous Solution Pen-injector 2 MG/1.5ML 01/10/2020 38.62 811.05 06/21/2033 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None NNI holds a number of patents related to Ozempic and has included the expiration date for Patent #10335462 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Ozempic and did not acquire the product from a different company.
Rx0000033 Novo 03/31/2020 00169406012 Victoza 6mg/mL 2x3mL Prefilled Pens 01/10/2020 30.72 645.24 07/09/2037 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None NNI holds a number of patents related to Victoza. We've included the expiration date for Patent #9968659 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Victoza and did not acquire the product from a different company.
Rx0000033 Novo 03/31/2020 00169406013 Victoza 6mg/mL 3x3mL Prefilled Pens 01/10/2020 46.08 967.86 07/09/2037 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None NNI holds a number of patents related to Victoza. We've included the expiration date for Patent #9968659 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Victoza and did not acquire the product from a different company.